Traded Jan 23, 2026 · Filed Jan 26, 2026
The boss of Abbott Laboratories paid $2.01M out of pocket for Abbott Laboratories shares. 1 other person at Abbott Laboratories bought some too, in the same month. The Abbott Laboratories shares held grew by 10%.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market purchase
Code P — open-market or private purchase
~$2,013,967
Shares × reported transaction price
$1M+
+9.5%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals about 8.3% of the CEO's reported total pay for fiscal 2025 ($24.2M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-03-13. The proxy names Robert B. Ford as CEO for that year. A size comparison, not a judgement
1 day after results of Jan 22, 2026, 83 days before results of Apr 16, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Congressional tradeSits on House Energy and Commerce9 different filers disclosed ABT within 90 days. Disclosed 21 days after the transaction; reported as an official range, not an exact amount.
A board member of Abbott Laboratories paid $542K out of pocket for Abbott Laboratories shares. 1 other person at Abbott Laboratories bought some too, in the same month.
A board member of Abbott Laboratories paid $545K out of pocket for Abbott Laboratories shares. 1 other person at Abbott Laboratories bought some too, in the same month.
